Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

Peter H. Schur, MD  |  Issue: December 2014  |  December 1, 2014

Know your labs
Laboratory testing is essential in the diagnosis and management of patients with rheumatic disease.

Editor’s note: This article originally appeared in The Rheumatologist in a two-part series in February and April 2009. The topic and this article remain highly relevant, and Dr. Schur has updated it here.

Laboratory testing is an essential element in the diagnosis and management of patients with rheumatic disease. This article focuses on a diverse array of serological markers that can provide unique information on the status of the patient’s immune system that is important in clinical evaluation as well as scientific inquiry. These tests help in the diagnosis of a particular disease, and importantly, they may help monitor disease activity. Indeed, immunological testing represents one of the bedrocks of rheumatology and is a distinguishing feature of our specialty.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although there are many available tests, the approach to serology follows the traditional approach of any laboratory study. Critical in the interpretation of any serological test is determining its sensitivity (i.e., that proportion of patients with the target disorder who have a positive test), specificity (i.e., that proportion of patients who are free of the target disorder and have negative or normal test results), and positive and negative predictive values, which calculate the likelihood that disease is present or absent based on test results using the test’s sensitivity, specificity and the probability of disease before the test is performed (pretest probability). This review covers data on antinuclear antibodies (ANAs) and tests for rheumatoid arthritis (RA).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Table 1: Sensitivity of the ANA in Autoimmune & Nonrheumatic Disease
click for large version
Table 1: Sensitivity of the ANA in Autoimmune & Nonrheumatic Disease

Antinuclear Antibodies

ANAs are the signature autoantibodies of the rheumatic disease and are tested in many clinical scenarios.1-3 These antibodies are usually detected by immunofluorescent (IF) techniques, utilizing Hep-2 cell lines, and specific antinuclear antibodies are detected by solid-phase immuno­assays—for example, an ELISA. One hundred and eighty autoantibodies have been described so far in patients with systemic lupus erythematosus (SLE).58 The IF ANA is generally screened at a dilution (i.e., titer) of 1:40, and, if positive, serial dilutions are carried out until a dilution is negative. Most labs titer to 1:1280, but some go higher. It is not clear whether titering higher is clinically useful, because the titer of an ANA usually does not correlate with clinical activity.

The IF ANA test is especially useful as an initial screen for patients suspected of having systemic lupus erythematosus (SLE). ANA testing is also useful for the evaluation of patients with other suspected rheumatic conditions including Sjögren’s syndrome, mixed connective tissue disease (MCTD), drug-induced lupus erythematosus, dermato-/polymyositis, scleroderma, adult and juvenile arthritis and autoimmune hepatitis. However, the presence of an ANA does not signify the presence of illness, because these antibodies may also be found in otherwise normal individuals. As shown in Table 1 (left), the sensitivity of the ANA for a particular autoimmune disease can vary widely.

Page: 1 2 3 4 5 6 7 8 9 10 11 | Single Page
Share: 

Filed under:ConditionsPractice SupportQuality Assurance/ImprovementSjögren’s Disease Tagged with:ANA titerantinuclear antibodiesantinuclear antibody testDiagnosislab testlabspatient careRheumatic DiseaseRheumatoid arthritisrheumatologistSchurSclerodermaSjogren's

Related Articles

    Know Your Labs

    February 1, 2009

    A review of state-of-the-art testing for SLE and connective tissue disease.

    Know Your Labs, Part 2

    April 1, 2009

    A review of testing for rheumatoid arthritis

    The Role of ANA Positivity in Patients with RA

    September 28, 2021

    Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses.

    Antiphospholipid Antibody Testing Update

    January 13, 2012

    Successes, challenges, and controversies of diagnostic methods for APS

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences